Shares of Ranbaxy Laboratories Ltd and Strides Arcolab Ltd dropped in Mumbai trading after the US raised manufacturing concerns following factory inspections.
The US Food and Drug Administration (FDA) issued an import alert against Ranbaxy’s plant in Mohali in India’s Punjab state, according to a notice dated on Friday.
Shares of Ranbaxy, the country’s largest drugmaker, dropped as much as 35 percent to 297.25 rupees, headed for the biggest loss since the shares started trading in January 1991.
“Some of the products they have filed from this unit will get postponed,” Rohit Bhat, a health-care analyst at B&K Securities India Pvt Ltd, said in a telephone interview. “The resolution of this unit might take another couple of years.”
Strides Arcolab Ltd said a facility in Bangalore received a warning letter after an inspection found reasons for concern. An import alert was placed on a Wockhardt Ltd factory in India in May. The checks may be a sign that the FDA is being more vigilant of overseas suppliers. The regulator inspects foreign drug facilities once every nine years on average, compared with once every 30 months for US plants, the US Government Accountability Office reported in September 2010.
Ranbaxy’s shares traded at 334.2 rupees, down by 27 percent, as of 11:42am and has lost a third of its value this year.
Strides’s shares fell as much as 6.8 percent to 839 rupees, headed for the biggest decline since Aug. 14.
Products from companies on the FDA’s import alert list may be subject to detention without physical examination.
Ranbaxy agreed in May to pay US$500 million to resolve fraud allegations made in a whistle-blower’s lawsuit and federal criminal charges that it sold batches of drugs that were improperly manufactured, stored and tested.
It also admitted to lying to the FDA about how it tested drugs at two of its Indian plants.
“It doesn’t seem that things have changed,” Bhat said. “Everyone knows that the company has been facing FDA compliance issues for their other units, but it was expected that they would have learned from earlier experiences and hoped that they would be able to clear the FDA for this unit.”
Strides responded to the FDA’s observations made during an inspection of a sterile manufacturing facility in Bangalore in June by implementing corrective actions, it said in a statement yesterday.
“The company is committed to work collaboratively and expeditiously with the US FDA to resolve concerns cited in the warning letter in the shortest possible time,” Strides said.
DECOUPLING? In a sign of deeper US-China technology decoupling, Apple has held initial talks about using Baidu’s generative AI technology in its iPhones, the Wall Street Journal said China has introduced guidelines to phase out US microprocessors from Intel Corp and Advanced Micro Devices Inc (AMD) from government PCs and servers, the Financial Times reported yesterday. The procurement guidance also seeks to sideline Microsoft Corp’s Windows operating system and foreign-made database software in favor of domestic options, the report said. Chinese officials have begun following the guidelines, which were unveiled in December last year, the report said. They order government agencies above the township level to include criteria requiring “safe and reliable” processors and operating systems when making purchases, the newspaper said. The US has been aiming to boost domestic semiconductor
Nvidia Corp earned its US$2.2 trillion market cap by producing artificial intelligence (AI) chips that have become the lifeblood powering the new era of generative AI developers from start-ups to Microsoft Corp, OpenAI and Google parent Alphabet Inc. Almost as important to its hardware is the company’s nearly 20 years’ worth of computer code, which helps make competition with the company nearly impossible. More than 4 million global developers rely on Nvidia’s CUDA software platform to build AI and other apps. Now a coalition of tech companies that includes Qualcomm Inc, Google and Intel Corp plans to loosen Nvidia’s chokehold by going
ENERGY IMPACT: The electricity rate hike is expected to add about NT$4 billion to TSMC’s electricity bill a year and cut its annual earnings per share by about NT$0.154 Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) has left its long-term gross margin target unchanged despite the government deciding on Friday to raise electricity rates. One of the heaviest power consuming manufacturers in Taiwan, TSMC said it always respects the government’s energy policy and would continue to operate its fabs by making efforts in energy conservation. The chipmaker said it has left a long-term goal of more than 53 percent in gross margin unchanged. The Ministry of Economic Affairs concluded a power rate evaluation meeting on Friday, announcing electricity tariffs would go up by 11 percent on average to about NT$3.4518 per kilowatt-hour (kWh)
OPENING ADDRESS: The CEO is to give a speech on the future of high-performance computing and artificial intelligence at the trade show’s opening on June 3, TAITRA said Advanced Micro Devices Inc (AMD) chairperson and chief executive officer Lisa Su (蘇姿丰) is to deliver the opening keynote speech at Computex Taipei this year, the event’s organizer said in a statement yesterday. Su is to give a speech on the future of high-performance computing (HPC) in the artificial intelligence (AI) era to open Computex, one of the world’s largest computer and technology trade events, at 9:30am on June 3, the Taiwan External Trade Development Council (TAITRA) said. Su is to explore how AMD and the company’s strategic technology partners are pushing the limits of AI and HPC, from data centers to